The Latest News and Notes, plus Conversation with Tom Mitro
Click Here to Manage Email Alerts
In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss the latest news and trends and chat with Tom Mitro about his career and impact in ophthalmology.
- Welcome to the Eyeluminaries podcast :02
- Review of episode 26 :58
- FDA grants fast track designation to brepocitinib for noninfectious uveitis 1:42
- I. Howard Fine, MD, esteemed ophthalmologist, dies 3:54
- First subjects dosed in phase 3 trial of phentolamine ophthalmic solution for presbyopia 5:48
- LENZ Therapeutics submits NDA for drops to treat presbyopia 7:57
- Intro of Tom Mitro 10:40
- Tell us about your journey in ophthalmology 12:38
- Tell us about the new dry eye drug from Signal 12. 15:53
- How much sensation is on the forehead if the drug is well tolerated? 24:13
- What are your thoughts on the current ophthalmology market? 26:01
- Tell us a funny story about Jim Mazzo and about John Hovanesian. 28:51
- Preview of episode 29 33:25
- Give us your feedback 34:34
- Thanks 34:50
John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California.
Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA.
Tom Mitro is the president and chief operating officer for Aerie Pharmaceuticals.
We’d love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian.
Collapse
Read more about
Click Here to Manage Email Alerts
